Merck’s fast-ascending kidney cancer drug hits a setback

Merck’s Phase 3 trial of Welireg in first-line clear cell renal cell carcinoma missed both primary endpoints at an interim analysis, derailing a potential label expansion in the largest kidney cancer setting. The setback lowers Welireg’s long-term revenue ceiling even as 2025 sales rose more than 40% to $716 million; shares fell about 4% on the news. Analysts had seen roughly $2.2 billion in 2030 sales, while a successful first-line expansion could have implied $5.8 billion in revenue potential.

Analysis

This is not just a one-off clinical miss; it meaningfully compresses the probability distribution on Welireg becoming a true “Keytruda replacement bridge” in kidney cancer. The market is likely to re-rate MRK less on current 2025 sales and more on the shrinking terminal-value contribution from the asset, because the incremental value was always in earlier-line, longer-duration use where each responder compounds revenue for years rather than months.

The first-order loser is Merck’s post-Keytruda earnings bridge, but the second-order loser may be Eisai’s Lenvima franchise if combo fatigue starts to set in around the class. When a three-drug regimen fails to beat a two-drug backbone, it reinforces the market’s skepticism that simply adding another branded agent into RCC will create durable differentiation; that can spill over into future trial read-throughs across the VEGF/HIF-2 ecosystem and tighten investor appetite for pipeline complexity.

Timing matters: the near-term downside is days-to-weeks from sell-side estimate cuts and multiple compression, while the larger reset is months-to-years if FDA momentum slows on the earlier-line expansion. The key reversal catalyst is not a mechanistic argument, but a cleaner dataset in another Litespark study or surprisingly strong commercial uptake in existing indications that proves Welireg can still scale without first-line RCC. If the pending label expansion is approved, the stock may stabilize, but the upside case for filling a future Keytruda gap has likely been structurally impaired.

Consensus may be underestimating how much of Welireg’s valuation was optionality, not base business. The current revenue run-rate can look healthy enough to disguise that the NPV was being driven by a small number of high-duration scenarios; removing one of the highest-value settings can cut long-term revenue expectations far more than the headline sales miss implies.

Key Decisions for Investors

• Short MRK on a 2-6 week horizon or buy downside via puts into any post-news bounce; risk/reward favors fading strength because this lowers the long-duration value of Welireg more than the stock’s current selloff implies.
• Pair trade: long a higher-quality large-cap pharma with less pipeline optionality risk versus short MRK for relative-value exposure; the thesis is that MRK’s multiple should compress as its post-Keytruda bridge narrows.
• If holding MRK, reduce exposure on rallies and wait for the next Litespark data point before re-adding; the current setup is a classic “good commercial quarter, bad asset trajectory” trap.
• For event-driven accounts, consider a short-dated put spread around the next analyst revision cycle; the likely catalyst is estimate cuts rather than immediate fundamental deterioration in reported sales.
• Avoid initiating long-only positions in mid-cap RCC beneficiaries until the market digests whether this is a class-wide signal or a Merck-specific trial design issue; the read-through risk is asymmetric to the downside.